Risk Factors for and Management of MPN-Associated Bleeding and Thrombosis
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Risk Factors for and Management of MPN-Associated Bleeding and Thrombosis
Authors
Keywords
Myeloproliferative neoplasm (MPN), Essential thrombocythemia (ET), Polycythemia vera (PV), Primary myelofibrosis (PMF), Thrombosis, Hemorrhage
Journal
Current Hematologic Malignancy Reports
Volume 12, Issue 5, Pages 389-396
Publisher
Springer Nature
Online
2017-09-25
DOI
10.1007/s11899-017-0400-3
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Clonal Hematopoiesis and Risk of Atherosclerotic Cardiovascular Disease
- (2017) Siddhartha Jaiswal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Incidence rates and case fatality rates of portal vein thrombosis and Budd-Chiari Syndrome
- (2017) Francesco Dentali et al. THROMBOSIS AND HAEMOSTASIS
- The effect of arterial hypertension on thrombosis in low-risk polycythemia vera
- (2016) Tiziano Barbui et al. AMERICAN JOURNAL OF HEMATOLOGY
- Diagnosis, prevention, and management of bleeding episodes in Philadelphia-negative myeloproliferative neoplasms: recommendations by the Hemostasis Working Party of the German Society of Hematology and Medical Oncology (DGHO) and the Society of Thrombosis and Hemostasis Research (GTH)
- (2016) Iris Appelmann et al. ANNALS OF HEMATOLOGY
- The impact of ruxolitinib on thrombosis in patients with polycythemia vera and myelofibrosis
- (2016) Bethany T. Samuelson et al. BLOOD COAGULATION & FIBRINOLYSIS
- Antiplatelet therapy versus observation in low-risk essential thrombocythemia with a CALR mutation
- (2016) A. Alvarez-Larran et al. HAEMATOLOGICA
- Ruxolitinib versus best available therapy in patients with polycythemia vera: 80-week follow-up from the RESPONSE trial
- (2016) S. Verstovsek et al. HAEMATOLOGICA
- Bleeding, thrombosis, and anticoagulation in myeloproliferative neoplasms (MPN): analysis from the German SAL-MPN-registry
- (2016) A. Kaifie et al. Journal of Hematology & Oncology
- High rate of recurrent venous thromboembolism in patients with myeloproliferative neoplasms and effect of prophylaxis with vitamin K antagonists
- (2016) V De Stefano et al. LEUKEMIA
- Antiplatelet therapy versus observation in low-risk essential thrombocythemia with a CALR mutation
- (2016) A. Alvarez-Larran et al. HAEMATOLOGICA
- Ruxolitinib versus best available therapy in patients with polycythemia vera: 80-week follow-up from the RESPONSE trial
- (2016) S. Verstovsek et al. HAEMATOLOGICA
- Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management
- (2015) Ayalew Tefferi et al. AMERICAN JOURNAL OF HEMATOLOGY
- Oral anticoagulation to prevent thrombosis recurrence in polycythemia vera and essential thrombocythemia
- (2015) Juan-Carlos Hernández-Boluda et al. ANNALS OF HEMATOLOGY
- Ruxolitinib versus Standard Therapy for the Treatment of Polycythemia Vera
- (2015) Alessandro M. Vannucchi et al. NEW ENGLAND JOURNAL OF MEDICINE
- In contemporary patients with polycythemia vera, rates of thrombosis and risk factors delineate a new clinical epidemiology
- (2014) T. Barbui et al. BLOOD
- Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia
- (2013) G. Rotunno et al. BLOOD
- Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial
- (2013) H. Gisslinger et al. BLOOD
- Splanchnic vein thrombosis in myeloproliferative neoplasms
- (2013) Mallika Sekhar et al. BRITISH JOURNAL OF HAEMATOLOGY
- Personalized management of essential thrombocythemia—application of recent evidence to clinical practice
- (2013) A Tefferi et al. LEUKEMIA
- Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study
- (2013) A Tefferi et al. LEUKEMIA
- Leukocytosis as an important risk factor for arterial thrombosis in WHO-defined early/prefibrotic myelofibrosis: An international study of 264 patients
- (2012) Veronika Buxhofer-Ausch et al. AMERICAN JOURNAL OF HEMATOLOGY
- Correlation of blood counts with vascular complications in essential thrombocythemia: analysis of the prospective PT1 cohort
- (2012) P. J. Campbell et al. BLOOD
- Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis)
- (2012) T. Barbui et al. BLOOD
- Leucocytosis and thrombosis at diagnosis are associated with poor survival in polycythaemia vera: a population-based study of 327 patients
- (2012) Gilles Bonicelli et al. BRITISH JOURNAL OF HAEMATOLOGY
- Cardiovascular Events and Intensity of Treatment in Polycythemia Vera
- (2012) Roberto Marchioli et al. NEW ENGLAND JOURNAL OF MEDICINE
- Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients
- (2011) A. Carobbio et al. BLOOD
- Philadelphia-Negative Classical Myeloproliferative Neoplasms: Critical Concepts and Management Recommendations From European LeukemiaNet
- (2011) Tiziano Barbui et al. JOURNAL OF CLINICAL ONCOLOGY
- Survival and Disease Progression in Essential Thrombocythemia Are Significantly Influenced by Accurate Morphologic Diagnosis: An International Study
- (2011) Tiziano Barbui et al. JOURNAL OF CLINICAL ONCOLOGY
- Incidence and risk factors for bleeding in 1104 patients with essential thrombocythemia or prefibrotic myelofibrosis diagnosed according to the 2008 WHO criteria
- (2011) G Finazzi et al. LEUKEMIA
- Observation versus antiplatelet therapy as primary prophylaxis for thrombosis in low-risk essential thrombocythemia
- (2010) A. Alvarez-Larran et al. BLOOD
- Thrombohemorrhagic complications of myeloproliferative disorders
- (2010) Emmanouil Papadakis et al. BLOOD REVIEWS
- A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications
- (2010) F Passamonti et al. LEUKEMIA
- Thrombosis in primary myelofibrosis: incidence and risk factors
- (2009) T. Barbui et al. BLOOD
- JAK2V617F allele burden and thrombosis: A direct comparison in essential thrombocythemia and polycythemia vera
- (2009) Alessandra Carobbio et al. EXPERIMENTAL HEMATOLOGY
- Influence of the JAK2 V617F mutation and inherited thrombophilia on the thrombotic risk among patients with essential thrombocythemia
- (2009) V. De Stefano et al. HAEMATOLOGICA
- Association of V617F Jak2 mutation with the risk of thrombosis among patients with essential thrombocythaemia or idiopathic myelofibrosis: A systematic review
- (2009) Federico Lussana et al. THROMBOSIS RESEARCH
- Effect of JAK2 V617F on thrombotic risk in patients with essential thrombocythemia: measuring the uncertain
- (2008) P. D. Ziakas HAEMATOLOGICA
- Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments
- (2008) V. De Stefano et al. HAEMATOLOGICA
- Leukocytosis and Risk Stratification Assessment in Essential Thrombocythemia
- (2008) Alessandra Carobbio et al. JOURNAL OF CLINICAL ONCOLOGY
- Is JAK2 V617F mutation more than a diagnostic index?
- (2008) Issa J. Dahabreh et al. LEUKEMIA RESEARCH
- Postsurgery outcomes in patients with polycythemia vera and essential thrombocythemia: a retrospective survey
- (2007) M. Ruggeri et al. BLOOD
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started